Publication: Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development
No Thumbnail Available
Open/View Files
Date
2017-09-26
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
eLife Sciences Publications, Ltd
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
França, Camila Tenorio, Michael T White, Wen-Qiang He, Jessica B Hostetler, Jessica Brewster, Gabriel Frato, Indu Malhotra, Jakub Gruszczyk, Christele Huon, Enmoore Lin, Benson Kiniboro, Anjali Yadava, Peter Siba, Mary R Galinski, Julie Healer, Chetan Chitnis, Alan F Cowman, Eizo Takashima, Takafumi Tsuboi, Wai-Hong Tham, Rick M Fairhurst, Julian C Rayner, Christopher L King, and Ivo Mueller. "Identification of Highly-protective Combinations of Recombinant Proteins for Vaccine Development." ELife 6 (2017):
Research Data
Abstract
The study of antigenic targets of naturally-acquired immunity is essential to identify and prioritize antigens for further functional characterization. We measured total IgG antibodies to 38 P. vivax antigens, investigating their relationship with prospective risk of malaria in a cohort of 1–3 years old Papua New Guinean children. Using simulated annealing algorithms, the potential protective efficacy of antibodies to multiple antigen-combinations, and the antibody thresholds associated with protection were investigated for the first time. High antibody levels to multiple known and newly identified proteins were strongly associated with protection (IRR 0.44–0.74, p<0.001–0.041). Among five-antigen combinations with the strongest protective effect (>90%), EBP, DBPII, RBP1a, CyRPA, and PVX_081550 were most frequently identified; several of them requiring very low antibody levels to show a protective association. These data identify individual antigens that should be prioritized for further functional testing and establish a clear path to testing a multicomponent P. vivax vaccine.